Carboplatin

BRCA1 DNA repair associated ; Homo sapiens







37 Article(s)
Download
PMID
Title
Pub. Year
#Total Relationships
1 35105904 Ovarian toxicity of carboplatin and paclitaxel in mouse carriers of mutation in BRIP1 tumor suppressor gene. 2022 Feb 1 1
2 35626017 Molecular Characterization of BRCA1 c.5339T>C Missense Mutation in DNA Damage Response of Triple-Negative Breast Cancer. 2022 May 13 2
3 32720318 Impact of the addition of carboplatin to anthracycline-taxane-based neoadjuvant chemotherapy on survival in BRCA1/2-mutated triple-negative breast cancer. 2021 Feb 15 4
4 33098992 Assessment of structural chromosomal instability phenotypes as biomarkers of carboplatin response in triple negative breast cancer: the TNT trial. 2021 Jan 1
5 33100178 Predictive factors for carboplatin hypersensitivity reactions in gynecologic cancers: Effect of BRCA status. 2021 Oct 2
6 33377156 Value of adjuvant chemotherapy and informed microscopic examination for occult gynecologic cancer detected upon risk-reducing salpingo-oophorectomy after chemotherapy for BRCA1/2-associated breast cancer: a case report. 2021 Mar 3 1
7 33690902 Differential treatment outcomes in BRCA1/2-, CDK12-, and ATM-mutated metastatic castration-resistant prostate cancer. 2021 Jun 15 1
8 33896588 Hypersensitivity to platinum salts according to BRCA status in ovarian cancer: A retrospective analysis of clinical outcomes and systematic review of literature. 2021 Jul 1
9 32194804 Sensitization of Carboplatinum- and Taxol-Resistant High-Grade Serous Ovarian Cancer Cells Carrying p53, BRCA1/2 Mutations by Emblica officinalis (Amla) via Multiple Targets. 2020 1
10 31080557 Phase I/Ib study of olaparib and carboplatin in heavily pretreated recurrent high-grade serous ovarian cancer at low genetic risk. 2019 Apr 23 2
11 31213465 Chromosome 12p Amplification in Triple-Negative/BRCA1-Mutated Breast Cancer Associates with Emergence of Docetaxel Resistance and Carboplatin Sensitivity. 2019 Aug 15 3
12 31821346 Establishment of chemosensitivity tests in triple-negative and BRCA-mutated breast cancer patient-derived xenograft models. 2019 1
13 33457057 Incidence of Hypersensitivity Reactions to Carboplatin or Paclitaxel in Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer With or Without BRCA1 or BRCA2 Mutations. 2019 Jul 6
14 29713086 Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. 2018 May 1
15 29804901 Responses to carboplatin in BRCA1/2-mutated breast cancer. 2018 Jul 1
16 27765459 Carboplatin-allergic patients undergoing desensitization: prevalence and impact of the BRCA 1/2 mutation. 2017 May - Jun 1
17 28222073 A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours. 2017 Mar 28 1
18 28356425 Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083. 2017 Aug 1 3
19 28577239 Population pharmacokinetic analyses of the effect of carboplatin pretreatment on olaparib in recurrent or refractory women's cancers. 2017 Jul 2
20 28715532 Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial. 2017 Oct 1 1
21 27060208 The autophagy inhibitor chloroquine targets cancer stem cells in triple negative breast cancer by inducing mitochondrial damage and impairing DNA break repair. 2016 Jul 1 1
22 25481791 Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. 2015 Jan 1
23 25499884 Carboplatin and taxol resistance develops more rapidly in functional BRCA1 compared to dysfunctional BRCA1 ovarian cancer cells. 2015 Aug 1 3
24 25665554 Assessing the role of platinum agents in aggressive breast cancers. 2015 Feb 1
25 25847929 Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105. 2015 Jun 10 1
26 24678242 Host Cell Reactivation and Transcriptional Activation of Carboplatin-Modified BRCA1. 2014 5
27 24842883 Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses. 2014 Jun 2
28 24887359 Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy. 2014 May 15 1
29 23522120 Exome profiling of primary, metastatic and recurrent ovarian carcinomas in a BRCA1-positive patient. 2013 Mar 22 1
30 23867999 Deleterious BRCA1/2 mutation is an independent risk factor for carboplatin hypersensitivity reactions. 2013 Aug 20 5
31 22778154 Enhancement of synthetic lethality via combinations of ABT-888, a PARP inhibitor, and carboplatin in vitro and in vivo using BRCA1 and BRCA2 isogenic models. 2012 Sep 1
32 22967451 [Docetaxel plus carboplatin versus EC-T as adjuvant chemotherapy for triple-negative breast cancer: safety data from a phase III randomized open-label trial]. 2012 Jun 1
33 20878461 The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by the platinum-based anticancer drugs. 2011 Feb 1
34 21368455 [PARP inhibitors for cancer therapy]. 2011 Jan 1
35 19955925 Does paclitaxel-carboplatin chemotherapy in a dose-dense regimen enhance survival of BRCA-related ovarian cancer patients? 2009 Dec 1
36 18547621 Xenografts of primary human gynecological tumors grown under the renal capsule of NOD/SCID mice show genetic stability during serial transplantation and respond to cytotoxic chemotherapy. 2008 Aug 2
37 16099593 In vitro platination of human breast cancer suppressor gene1 (BRCA1) by the anticancer drug carboplatin. 2005 Sep 15 5